Therapeutic Response

HER2-positive and PR positive status confers therapeutic sensitivity to Lapatinib in combination with Letrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description

Tykerb (lapatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.